Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Efficacy and safety of rivaroxaban versus placebo...
Journal article

Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD

Abstract

BACKGROUND: The Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) trial is the only large, double-blind, placebo-controlled trial of dual antiplatelet therapy (DAPT) versus aspirin in patients with peripheral artery disease (PAD) after lower extremity revascularization (LER). The trial was neutral for index-graft occlusion/revascularization, amputation or death (hazard ratio [HR] 0.98, 95% …

Authors

Bonaca MP; Szarek M; Debus ES; Nehler MR; Patel MR; Anand SS; Muehlhofer E; Berkowitz SD; Haskell LP; Bauersachs RM

Journal

Clinical Cardiology, Vol. 45, No. 12, pp. 1143–1146

Publisher

Wiley

Publication Date

December 2022

DOI

10.1002/clc.23926

ISSN

0160-9289